|
|
Line 11: |
Line 11: |
|
| |
|
| DDx: | | DDx: |
| *[[Papillary renal cell carcinoma]].<ref name=pmid29685646>{{Cite journal | last1 = Pal | first1 = SK. | last2 = Bergerot | first2 = P. | last3 = Dizman | first3 = N. | last4 = Bergerot | first4 = C. | last5 = Adashek | first5 = J. | last6 = Madison | first6 = R. | last7 = Chung | first7 = JH. | last8 = Ali | first8 = SM. | last9 = Jones | first9 = JO. | title = Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma. | journal = Eur Urol | volume = 74 | issue = 1 | pages = 124-128 | month = 07 | year = 2018 | doi = 10.1016/j.eururo.2018.03.032 | PMID = 29685646 }}</ref> - especially "type 2".<ref name=pmid24255633/> | | *[[Papillary renal cell carcinoma]] - especially "type 2".<ref name=pmid24255633/> |
| *[[Unclassified renal cell carcinoma]] | | *[[Unclassified renal cell carcinoma]] |
| *[[Renal medullary carcinoma]]. | | *[[Renal medullary carcinoma]]. |